All Outputs (33)

High procedure volume is strongly associated with improved survival after lung cancer surgery (2013)
Journal Article
Lüchtenborg, M., Riaz, S. P., Coupland, V. H., Lim, E., Jakobsen, E., Krasnik, M., …Møller, H. (2013). High procedure volume is strongly associated with improved survival after lung cancer surgery. Journal of Clinical Oncology, 31(25), 3141-3146. https://doi.org/10.1200/JCO.2013.49.0219

Purpose Studies have reported an association between hospital volume and survival for non–small-cell lung cancer (NSCLC). We explored this association in England, accounting for case mix and propensity to resect. Methods We analyzed data on 134,293... Read More about High procedure volume is strongly associated with improved survival after lung cancer surgery.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., …Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? (2012)
Journal Article
Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., …Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), 1276-1283. https://doi.org/10.1016/j.jprot.2011.11.005

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only thos... Read More about Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?.

Differential proteomics in the search for biomarkers of radiotherapy resistance (2011)
Journal Article
Scaife, L., Hodgkinson, V. C., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Differential proteomics in the search for biomarkers of radiotherapy resistance. Expert Review of Proteomics, 8(4), 535-552. https://doi.org/10.1586/EPR.11.32

The individualization of radiotherapy treatment would be beneficial for cancer patients; however, there are no predictive biomarkers of radiotherapy resistance in routine clinical use. This article describes the body of work in this field where compa... Read More about Differential proteomics in the search for biomarkers of radiotherapy resistance.

A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer (2011)
Journal Article
ELFadl, D., Hodgkinson, V. C., Long, E. D., Scaife, L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. The Breast : official journal of the European Society of Mastology, 20(4), 334-337. https://doi.org/10.1016/j.breast.2011.02.017

Breast conserving therapy is a currently accepted method for managing patients with early stage breast cancer. However, approximately 7% of patients may develop loco-regional tumour recurrence within 5 years. We previously reported that expression of... Read More about A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.

Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis (2011)
Journal Article
Hodgkinson, V. C., ELFadl, D., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics, 74(5), 698-703. https://doi.org/10.1016/j.jprot.2011.02.014

Antibody microarrays are powerful new tools in the field of comparative proteomics. The success of the biomarker discovery pipeline relies on the quality of data generated in the discovery phase and careful selection of proteins for the verification... Read More about Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? (2010)
Journal Article
Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), 533-542. https://doi.org/10.1016/j.ctrv.2010.11.004

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant... Read More about Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?.

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status (2010)
Journal Article
Hodgkinson, V. C., Eagle, G. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Letters, 294(1), 13-24. https://doi.org/10.1016/j.canlet.2010.01.036

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (... Read More about Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., …Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.